Amphastar Pharmaceutical Aktie - Fundamentalanalyse - Dividendenrendite KGV

Amphastar Pharmaceuticals Inc. (ISIN: US03209R1032, WKN: A11664 ) Kursdatum: 19.06.2018 Kurs: 16,960 USD
Beschreibung Daten
Symbol AMPH
Marktkapitalisierung 820.304.320,00 USD
Land Vereinigte Staaten von Amerika
Indizes NO INDEX
Sektor Pharma
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet ir.amphastar.com
Letztes Bilanz Update 16.03.2018

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 19.06.2018
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
199,59 20,92 0,00% 0,96 74,19 188,44 3,42 2,43

Firmenbeschreibung

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Die Finanzoo GmbH übernimmt keine Haftung für die Richtigkeit der Angaben! Alle Angaben sind ohne Gewähr. Quellen: www.bundesanzeiger.de, www.sec.gov, ir.amphastar.com